Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07126873
A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of E-islet 01 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Sponsor: EndoCell Therapeutics, Inc.
Interventions
Allogeneic Human E-islet (E-islet 01)
Updated 1 time since 2025 Last updated: Aug 17, 2025 Started: Aug 11, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Diabetes Mellitus, Type 1 and Impaired Hypoglycemic Awareness, this trial is actively recruiting participants. The trial is conducted by EndoCell Therapeutics, Inc. and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- EndoCell Therapeutics, Inc.
Data source: EndoCell Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .